NasdaqCM - Nasdaq Real Time Price USD

BioLife Solutions, Inc. (BLFS)

21.89

+0.74

+(3.50%)

At close: April 22 at 4:00:02 PM EDT

22.33

+0.44

+(2.01%)

Pre-Market: 7:21:28 AM EDT

Shareholders have faith in loss-making BioLife Solutions (NASDAQ:BLFS) as stock climbs 8.7% in past week, taking five-year gain to 112%

BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders might be concerned after seeing the share price drop 16% in the...

Simply Wall St. 7 days ago

BLFS
+3.50%
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?

Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 13 days ago

PODD

BLFS
+3.50%
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position as the market leader in biopreservation, en

PR Newswire 15 days ago

BLFS
+3.50%
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes

The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, WLDN, NXT, NVO and EZPW

Zacks 29 days ago

NVO

BLFS
+3.50%
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee.

PR Newswire last month

BLFS
+3.50%
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment

The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.

Zacks last month

BLFS
+3.50%
GBX

BHLB
BioLife Solutions Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioLife Solutions ( NASDAQ:BLFS ) Full Year 2024 Results Key Financial Results Revenue: US$82.3m (down 43% from FY...

Simply Wall St. last month

BLFS
+3.50%
BioLife Solutions Inc (BLFS) Q4 2024 Earnings Call Highlights: Strong Margin Growth and ...

BioLife Solutions Inc (BLFS) reports significant improvements in gross margin and EBITDA, despite a drop in total revenue due to strategic divestitures.

GuruFocus.com last month

BLFS
+3.50%
Q4 2024 BioLife Solutions Inc Earnings Call

Q4 2024 BioLife Solutions Inc Earnings Call

Thomson Reuters StreetEvents last month

BLFS
+3.50%
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BLFS
+3.50%
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announces financial results for the fourth quarter and year ended December 31, 2024, and introduces 2025 financial guidance.

PR Newswire last month

BLFS
+3.50%
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

PR Newswire last month

BLFS
+3.50%
Discover 3 US Stocks Estimated To Be Trading At Discounts Of Up To 41.5%

As of February 2025, the U.S. stock market has shown resilience, with the S&P 500 closing just shy of a record high and major indexes posting weekly gains despite mixed economic signals such as declining retail sales and fluctuating treasury yields. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities at discounted prices; these stocks may offer potential for growth when their true value is realized in the market.

Simply Wall St. 2 months ago

BLFS
+3.50%
SEDG

ENPH
Breakeven On The Horizon For BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions, Inc. ( NASDAQ:BLFS ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 2 months ago

BLFS
+3.50%
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?

BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks 2 months ago

BLFS
+3.50%
PAHC
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

Zacks 2 months ago

BLFS
+3.50%
BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 2 months ago

BLFS
+3.50%
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations.

PR Newswire 3 months ago

BLFS
+3.50%
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?

BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...

Simply Wall St. 3 months ago

BLFS
+3.50%
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six.

PR Newswire 4 months ago

RGEN

BLFS
+3.50%

Performance Overview

Return	BLFS	S&P 500 (^GSPC)
YTD	-15.68%	-10.10%
1-Year	+30.30%	+5.53%
3-Year	+73.87%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioLife Solutions, Inc. (BLFS)

Shareholders have faith in loss-making BioLife Solutions (NASDAQ:BLFS) as stock climbs 8.7% in past week, taking five-year gain to 112%

Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?

BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes

BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment

BioLife Solutions Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioLife Solutions Inc (BLFS) Q4 2024 Earnings Call Highlights: Strong Margin Growth and ...

Q4 2024 BioLife Solutions Inc Earnings Call

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results

BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

Discover 3 US Stocks Estimated To Be Trading At Discounts Of Up To 41.5%

Breakeven On The Horizon For BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?

Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Performance Overview